



GYNECOLOGIC CANCER INTERGROUP (GCIG)

MEMBERSHIP - GENERAL ASSEMBLY

FRIDAY, JUNE 1, 2012, 10:15 A.M. , CHICAGO, USA

MINUTES

Present:

Chair: M.Quinn; Chair-elect: E.Pujade-Lauraine; Secretary-Treas/Operations: M.Bacon; webmaster: S.Easley; Ovary Chair: C.Marth; Endometrial Chair: D.Miller; Cervix Chair: B.Small; Harm. Ops Chair: J.Martyn; Harm. Stats Chair: M.Brady; Trans.Research Chair: M.Birrer; SymptomBenefit Chair: M.Friedlander; Rare Tumours Chair: D.Gershenson; non-member Director: G.Stuart; Past Chair & CCRN Chair: H.Kitchener; non-member Director: J Vermorken; Membership Chair: J.Pfisterer.

Members:

ACRIN: S.Lee (Regrets: M.Atri)
AGO-Au: P.Speiser, A.Zeimet, G.Bogner, B.Volgger (Regrets: D.Pils)
AGO-de: P.Harter, S.Polleis, A.Reuss, J.Sehouli, F Hilpert, S.Mahner
ANZGOG: K.Narayan, C.Scott, L.Mileshkin, A.Brand, D.Rischin (Regrets: Chee)
COGI: J.Berek, A.Buchin, C.Chu, L.Kandalaf
DGOG: N.Ottevanger (Regrets: C.Creutzberg, K.Adema, E.Witteveen, W.van Driel, R.Bekkers)
EORTC-GCG: A.Casado, A.Negrout, S.Greggi (Regrets: D.Lacombe, I.Vergote, M.van der Berg)
GEICO: J.del Campo, A.Gonzalez, J.Lopez-Guerrero, F.Nepote, A.Poveda (Regrets: A.Oaknin)
GICOM: D.Gallardo, J.Hurtado, P.Cabrera, E.Gomez, D.Cantu, J.Coronel
GINECO: F.Joly, N.Le Fur, I.Ray-Coquard, B.Votan, AC.Hardy, Lecuru, Kurtz
GOG: B.Monk, B.Stonebraker, T.Thigpen, M.Bookman, R.Alvarez, G.Fleming
GOTIC: K.Fujiwara, T.Hamano, S.Nagao, T.Satoh, H.Fujiwara
ICORG: D.O'Donnell, A.Shevlin (Regrets: N.Gleeson, P.Calvert, B.Hennessey, S.O'Reilly)
JGOG: K.Ochiai, E.Aotani, H.Michimae, M.Mandai, N.Susumu, (Regrets: D. Aoiki, S.Sagae)
KGOG: J-W.Kim, B-H.Nam, S-Y.Ryu, JH.Kim, S.Kang, S-Y.Park (Regrets: J-S.Kim)
MaNGO: R.Fossati, N.Colombo (Regrets: D.Katsaros, P.Zola, A.Lissoni)
MITO: J.Bryce, D.Lorusso, F.Bellati, D.Mezzanonica, G.Daniele (Regrets: S.Pignata, R.Sorio)
MRC/NCRI: I.McNeish, L.James, A.Clamp, S.Blagden, C.Gourley, J.Hook (Regrets: M.McCormack, L.Farrelly, J.Ledermann)
NCIC CTG: H.Hirte, M.FungKeeFung, A.Hiltz, D.Provencher, J.McAlpine, D.Tu
NSGO: G.Andersen, G.Kristensen, M.Mirza, E.Avall, K.Woie (Regrets: U.Puistola)
RTOG: D.Gaffney, K.Winter, P.Eifel, A.Jhingran, A.Viswanathan, L.Portelance
SGCTG: R.Glasspol, J.Paul, K.Carty (Regrets: S.Kaye, N.Siddiqui, D.Millan)
SGOG: R.Zang, X.Wang, J.Zhu

Nat'l Authority:

NCI US: J.Zujewski, T.Trimble, B.Greer, W.Naumann, G.Thomas,

Observers:

Cuba: [regrets: A.Linchenat]
Saudi Arabia: [regrets: M.Mohiuddin, D.Ajarim]

Industry Partners:

Amgen: B.Allen, D.Warner
AstraZeneca: G.Locker
BoehringerIngelheim: B.vanEijk, M.Merger (N.Morsli)
EliLilly: T.Bauknecht, D.F.Tai
GSK: R.Crescenzo
JnJ(Ortho-Bio): S.Tardiff (Regrets: D.Atlan)
Pharmamar: P.Zintl, N.Badri
Roche: D.Bollag, V.Sneller
TAIHO: regrets
ZERIA: H.Kato

Guests: J.Schink for ISSTD

Welcome & Introductions (COI declaration)

Quinn

Secretariat Report

- Operations Manager: (full report presented to Executive/Board of Directors - minuted) Bacon
 - Minutes September 2011 (amended to add AC Hardy as Director for GINECO)
Motion – McNeish; seconded – Pfisterer; all in favour.
 - Attendance report – 138 registrations from 24 member groups, 9 industry partners and guests
 - Finances - Accounts reported to Exec-BoD and approved
 - invoices for 2012-2013 dues forthcoming
 - 10 Harmonization reps applied/approved for travel support
 - audit by Withey Addison completed April 30, 2012
 - annual submissions to Revenue Canada (taxes) and Industry Canada (incorp) done
 - Attendance Sheets circulating – please sign in.

- Webmaster: (full report presented to Executive/Board of Directors -- minuted) Easley
 - farewell and gratitude to M.Powers, welcome to S.Easley
 - Website update – ongoing
 - Attendance certificates available
 - Roster reminder –all groups asked to update webmaster
 - GCIG Publications and bibliography will be updated on website with input from groups
 - Trials Spreadsheets – to be developed by Committee Chairs with webmaster (for pre-meeting distribution)
 - Trial concept submission form – template in development

Membership Committee (full report presented to Executive/Board of Directors -- minuted)

Pfisterer/Stuart/Kitchener

- 3 provisional and 23 member groups were recently reviewed. Approved renewals at Exec-BoD. Several groups will receive reminders about Harmonization representation requirements.
Uncertain implications of unification of US groups (GOG + RTOG + NSABP)
 - Industry partners to be surveyed on perceived value and mutual benefits.
 - Mentorship guidelines are in development. Recommended that each new group be mentored by a seasoned member group (both Investigator and Harmonization Ops rep)
 - PMHC (Princess Margaret Hospital Consortium) Canada has applied for membership, fulfilling all criteria, and approved by Exec-BoD.
- Gratitude expressed to Pfisterer – outgoing Chair.

Executive-Board of Directors Report (see Exec-BoD minutes for full report)

Quinn

- Exec-BoD Recommendation: increase minuted current number of Directors from 27 to 30 (bylaws permit up to 40) to allow new member groups and non-member Directors. No objections received from membership in attendance.
- Updated Governance & Statutes document (May 2012) to be consistent with bylaws: distributed, reviewed and approved by Exec-BoD and will be posted on the website. action: Easley
- New co-Chairs for Committees & Working Groups elected. Terms begin autumn 2012.
- 5th OCCC confirmed for Tokyo, November 7-10, 2015.
- Quality Assurance: Exec-BoD recommendation: QA minimum standards be established for GCIG membership (eg: monitoring & auditing). Subcommittee formed to address this: Quinn, Ottevanger, Thigpen, O'Donnell, Gaffney, Fujiwara, Gallardo, & reps from Harmonization Ops.
- Concerns re: conflicts with ASCO (Friday) sessions: rejection of rescheduling to Wed-Thurs. Exec-BoD recommends efficiency: day 2: earlier start time (7:00am); circulate standardized trial spreadsheets beforehand; shorten Committee/working group meetings to 90 minutes each; Committees/working groups only report "what's new" at General Assembly; and, member groups & Industry Partners be solicited beforehand as to reportable items for General Assembly.
- Principles of Independence document distributed and reviewed. Exec-BoD: no revisions at this time.
- Autumn 2013 dates finalized: Nov. 16 – 17, London, UK.
- Proposal of increased funding of delegates discussed. Exec-BoD resolved: Harmonization reps travel support policy remains unchanged; invited guest/expert speakers may request some support (Exec.Committee/Officers will approve or not); local GCIG initiatives (eg: En Ca CTPM) may request support (to Exec Officers via Operations) and may be supported up to \$10,000. CAD.

Member Groups Updates/News – all groups called upon; most declined to make comments.

JGOG – Ochiai -- confirmed welcome to 5th OCCC in 2015

EORTC-GCG – Casado – Tarceva study results

GEICO – Poveda – all are invited to gyne. Onc.conference in Valencia, March 2013.

And, mentoring of Cuban group continues.

NCIC CTG – FungKeeFung – OV 21 (Ov IP study) continues to welcome new partners.

RTOG – Gaffney – will keep GCIG updated re: GOG/RTOG/NSABP merger.

SGOG – Zang – brief presentation of research initiatives.

Observer group : Cuba sends regrets.

Industry Partners : introduced AMGEN, ASTRA-ZENECA, BOEHRINGER INGELHEIM, ELI LILLY, GLAXO SMITH KLEIN, JOHNSON & JOHNSON, PHARMAMAR, ROCHE, ZERIA (Regrets: TAIHO) Quinn

Guests: reminder of \$50. fee for dinner guests to be paid to Ops Manager/Secty-Treas.

Quinn

Disease Site Committee Reports:

Endometrial Cancer (+GTD)

- Standing Committee report (see **report on website**)
- Gratitude to Miller (outgoing Chair)

Miller/Lorusso/Greggi

Endometrial Cancer – Clinical Trials Planning Meeting (CTPM) & SB brainstorming:

Kitchener/Friedlander/Bacon

*CTPM Scientific Programme and invited speakers well underway (Creutzberg) (Dec.1 9:00am-5:30pm).

*Symptom Benefit working group will hold a concurrent En Ca brainstorming (Dec.1 1:00pm – 5:30pm)

*GCIG reps (2-3 per member group for CTPM and 1 per member group for SB) will register via autumn GCIG Registration process.

* Outcomes of both will be reported at General Assembly (Dec.2)

Cervix Cancer (+ vulvar, vagina)

- Standing Committee report and SB Cx Ca report (see **reports on website**) **Small/Sagae/Monk**
 - Gratitude to Small (outgoing Chair)
- GCIG Cervix Cancer Research Network (CCRN) update (see report on website) **Kitchener/Gaffney**

Ovarian Cancer

- Standing Committee report (see **report on website**) **Marth /Harter/Gonzalez**
 - Gratitude to Marth (outgoing Chair)
- Symptom Benefit working group (see **report on website**) **Friedlander/Joly/McAlpine**
 - Gratitude to Friedlander (outgoing and longstanding founding Chair)
- Response/Progression/CA 125 – no news Thigpen

Harmonization Committee Report

- Operations (see **report on website**) **Martyn/Bryce/Stonebraker**
Gratitude to Martyn (outgoing Chair)
- Statisticians (see **report on website**) **Brady/Paul/Nam**
Gratitude to Brady (outgoing Chair)

Translational Research Committee Report: (see **report on website**)

Gratitude to Birrer (outgoing Chair) **Birrer/McNeish/Scott**

Working Groups Reports;

Rare Tumours (incl. carcinosarc. and borderline) (see **report on website**)

Gratitude to Gershenson (outgoing Chair) **Gershenson/Ray-Coquard/Ledermann**

FIGO Update: next FIGO meeting in October 2012; stay tuned.

Quinn

Adjourn

Next Meetings

- December 1 & 2, 2012, Leiden, Netherlands (Dec.1 EnCa CTPM)
- May 30 & 31, 2013, Chicago (ASCO)
- November 16 & 17, 2013, London, UK (Day 1 Rare Tumours)
- June 2014, Chicago (ASCO)
- Autumn 2014, Melbourne, Australia (IGCS) (Day 1 Cx Ca CTPM)
- June 2015, Chicago (ASCO)
- November 11 & 12, 2015, Tokyo, Japan (+ 5th OCCC Nov. 7-10 Tokyo) (ASGO Nov.13-15 Seoul, Korea)

Respectfully Submitted
Monica Bacon
GCIG Operations Manager

1:00pm: Executive Board meeting
2:00pm – 7:00pm GCIG Trial specific satellite meetings